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Background: The translocation t(9;11)(p22;q23) leading to the leukemogenic fusion gene MLL-AF9 is a frequent
translocation in infant acute myeloid leukemia (AML). This study aimed to identify genes and molecular processes
downstream of MLL-AF9 (alias MLL-MLLT3) which could assist to develop new targeted therapies for such leukemia
with unfavorable prognosis.
Methods: In the AML cell line THP1 which harbors this t(9;11) translocation, endogenous MLL-AF9 was silenced via
siRNA while ensuring specificity of the knockdown and its efficiency on functional protein level.
Results: The differential gene expression profile was validated for leukemia-association by gene set enrichment
analysis of published gene sets from patient studies and MLL-AF9 overexpression studies and revealed 425 differentially
expressed genes. Gene ontology analysis was consistent with a more differentiated state of MLL-AF9 depleted cells,
with involvement of a wide range of downstream transcriptional regulators and with defined functional processes such
as ribosomal biogenesis, chaperone binding, calcium homeostasis and estrogen response. We prioritized 41 gene
products as candidate targets including several novel and potentially druggable effectors of MLL-AF9 (AHR, ATP2B2,
DRD5, HIPK2, PARP8, ROR2 and TAS1R3). Applying the antagonist SCH39166 against the dopamine receptor DRD5
resulted in reduced leukemic cell characteristics of THP1 cells.
Conclusion: Besides potential new therapeutic targets, the described transcription profile shaped by MLL-AF9 provides
an information source into the molecular processes altered in MLL aberrant leukemia.
Keywords: Acute myeloid leukemia, MLL-AF9, Fusion gene, siRNA, Gene expression, Therapeutic targets, Molecular
processes, SCH39166, EcopipamBackground
The MLL gene has been found translocated to over 50
different partner genes in acute leukemia. Certain part-
ner genes are associated with distinct leukemia sub-
types, e.g. MLL-AF4 with pro B acute lymphoblastic
leukemia (ALL) and MLL-AF9, -AF6 and -AF10 with
acute myeloid leukemia (AML) of M4 and M5 subtypes
(French–American–British classification) [1]. MLL-AF9
(alias MLL-MLLT3) results from the translocation t(9;11)
(p22;q23) and is sufficient to initiate acute leukemia in
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distribution, and reproduction in any mediumrapidly acquired [2,3]. MLL and AF9 wildtype proteins
play essential roles in embryogenesis and hematopoiesis
[4-6] and are parts of protein complexes leading to tran-
scriptional initiation (MLL) and elongation (AF9) of target
genes [7,8]. The fusion protein MLL-AF9 is believed to
combine these properties, leading to increased activation
of target genes via transcriptional initiation and elong-
ation. MLL-AF9 is the most frequent fusion gene in infant
AML and especially associated with monoblastic AML
(M5) [9,10]. New targeted therapies are needed for this
type of leukemia with poor prognosis.
Novel therapeutic strategies which aim to intervene with
DNA binding of MLL directly or with the assembly of
MLL fusion protein with elongation complexes have been
discussed [7]. However, drug targeting of protein-proteinntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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the fact that they are not frequently targeted by approved
drugs [11]. An additional concern is that the wildtype
functions of the involved proteins would be abrogated as
well, leading to toxicity [7].
For these reasons, we specifically explored downstream
effects of MLL-AF9 in order to identify new alternative
drug targets for MLL-AF9 positive AML. Some previous
studies have analyzed targets of MLL-AF9 in in vivo
mouse models [3,12,13] or through lentiviral MLL-AF9
transduction [14]. MLL-AF9 expression and the associated
leukemogenic potential is significantly higher after retro-
viral transduction as compared to Mll-AF9 knockin and
impacts biologic properties like myeloid colony formation
and long term self-renewal capacity [3]. We thus altered
the endogenous level of MLL-AF9 through specific and ef-
ficient siRNA knockdown in the human monoblastic cell
line THP1 and studied the downstream effects. The com-
prehensive gene expression profile after MLL-AF9 deple-
tion suggested several cellular processes and 41 genes as
likely mediators of MLL-AF9 leukemogenic effects. Among
those, seven gene products were selected as candidate drug
targets. Functional relevance of one of these, the dopamine
receptor DRD5, was confirmed as an antagonist resulted in
reduced leukemic cell characteristics of THP1 cells.
Results
Specific siRNA knockdown of MLL-AF9
To specifically target MLL-AF9 without disturbing MLL
and AF9 wildtype expression levels, siRNAs were designed
to target the THP1 specific fusion point of MLL-AF9 tran-
script (Figure 1A). Off-target effects were controlled by util-
izing two different MLL-AF9 specific as well as two
different non-targeting control siRNAs. An experimental
setup with prolonged knockdown ofMLL-AF9 (over 8 days)
was chosen, because (1) the half-life of MLL-AF9 protein is
unknown and (2) MLL-AF9 is believed to lead to changes
in the expression of target genes via epigenetic mechanisms
[7,8] whose reversal may take a long time [15] thus leading
to a delayed effect on transcriptional level.
Mean transfection efficiency of THP1 cells was 93%
and mean cell viability after transfection was likewise
93%. Knockdown of MLL-AF9 reduced the transcript
levels on day 8 of experiments to 22.3 ± 6% residual ex-
pression (Figure 1B). MLL and AF9 wildtype transcript
levels were not significantly altered.
To ensure an effective MLL-AF9 knockdown on func-
tional protein level, we quantified HOXA9: Transcription of
HOXA9 is raised by MLL-AF9 through direct interaction
between MLL-AF9 protein complex and the HOXA9 pro-
moter [16,17]. HOXA9mRNA was reduced to 56.9 ± 8% re-
sidual expression on day 8 of MLL-AF9 knockdown
(Figure 1B). Additionally, immunoblotting confirmed an ef-
ficient reduction of MLL-AF9 on protein level (Figure 1C).Differentially expressed genes after MLL-AF9 knockdown
The prolonged knockdown of MLL-AF9 in THP1 cells
yielded 571 probes representing transcripts of 425 genes
as differentially expressed between knockdown and con-
trol treatments (Additional file 1, includes all accession
numbers). Gene expression profiling data have been de-
posited in NCBI’s Gene Expression Omnibus (GEO) [18]
and are available under the accession number GSE36592.
A number of previously defined criteria [19] supported
the high quality of our gene expression data. These in-
cluded the presence of important marker genes as ex-
pected for the study (i.e. probes detecting MLL-AF9 and
transcripts of the HOXA cluster), a reasonable number
of differentially expressed genes which were enriched in
certain biological processes as well as a significant cor-
relation between microarray and RT-qPCR data of inde-
pendent experiments (p 0.004, Spearman’s Rho 0.72).
We further validated our entire expression data set
for concordance with known gene regulatory effects of
MLL-AF9 via gene set enrichment analysis (GSEA). We
detected significant enrichments of direct MLL-AF9 tar-
gets identified in a mouse model [13] (Figure 2A) and of
genes downstream of MLL-AF9 identified in transduced
primary human cells [14] (Additional file 2). In the latter,
we observed a stronger enrichment of gene sets gener-
ated from human neonatal CD34+ cells as compared to
adult CD34+ cells.
Genes differentially expressed after MLL-AF9 knockdown
are associated with leukemia
The functional disease ontology database (FunDO) con-
tains curated preexisting evidence on genes associated
with disease entities. Applying FunDO analysis on our
set of 425 differentially expressed genes, Leukemia was
the most significant disease term associated with MLL-
AF9 depletion (fold enrichment (FE) = 7.7; Bonferroni
corrected p-value = 9.7 × 10-11). GSEA, which takes
into account the entire gene expression profile without
employing a significance cutoff value, confirmed the
leukemia gene set predefined by FunDO as being sig-
nificantly enriched (Figure 2B).
We further asked if our differential gene expression pro-
file after MLL-AF9 knockdown in THP1 cells is in agree-
ment with preexisting knowledge from in vivo studies.
Using GSEA, we found accordance (FDR q-value < 0.05)
to MLL-aberrant and myeloid leukemia patient studies
[1,20-23] (Table 1 and Additional file 3: Figure S1).
MLL-AF9 regulated genes are involved in defined
cellular processes
Functional bioinformatic analysis via DAVID resulted in
31 enriched gene ontology annotation terms with potential
biological relevance (Figure 3, Additional file 4). These
terms were selected out of 312 significantly enriched
Figure 1 SiRNA knockdown of MLL-AF9 in THP1 cells. (A) Alignments of siRNAs to MLL-AF9 mRNA. Bold sequence represents the MLL part of
the fusion transcript. (B) Confirmation of MLL-AF9 knockdown via RT-qPCR. Mean relative MLL-AF9 and HOXA9 transcript levels of knockdown
(siRNA-A, siRNA-B) as compared to control treatments (control siRNA-1, -2) during the time course of experiments. Graph represents data from five
independent experiments. Bars indicate standard deviation. (C) Immunoblot of MLL-AF9 from total protein extracted from day 8 experimental
samples. Normalized MLL-AF9 levels are indicated at the bottom.
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redundant terms and by evaluating their biological rele-
vance as recommended [19]. To structure the results,
the enriched annotation terms were manually assorted
to functional higher-order terms according to their
major role in the biological setting under investigation
(Figure 3 and details in Additional file 3: Table S1).
The higher-order term proliferation and apoptosis
contained 7 annotation-terms and suggested influence
of MLL-AF9 on cell replication (regulation of DNA rep-
lication), proliferation (JAK-STAT cascade, response to
wounding, cytokine binding) and apoptosis (regulation
of apoptosis, protein kinase C activity). Several genes
involved in replication or anti-apoptotic processes were
down-regulated (CALR, NPM2, POT1, STRA8 andMEF2C, SOCS2, SOX4 respectively) while several genes
encoding pro-apoptotic regulators were up-regulated
(CEBPB, DUSP1, HIPK2, LCK, NOTCH2, PRKCE,
TGFBR1, TRIO,VDR).
The higher-order term monocyte/macrophage differenti-
ation included 16 annotation terms that encompassed
fundamental functions of monocytes and macrophages
like antigen processing and presentation of peptide or poly-
saccharide antigen via MHC class II, phagocytosis and
marker of the hematopoietic cell lineage. Additionally, we
observed a raised expression of the monocytic maturation
marker CD14, CEBPB, EGR2, FOS, MAFB, MNDA and
MHC class II as well as a reduced expression of markers
of immature cells of the monocytic lineage (ELANE and
CTSG) [24-27].
Figure 2 Gene set enrichment plots for our gene expression profile after knockdown of MLL-AF9 in THP1 cells. (A) Gene set enrichment
plot of direct MLL-AF9 targets previously detected by Bernt et al. [13] in a mouse model. (B) Gene set enrichment plot of the leukemia gene set
defined by FunDO. Because MLL-AF9 acts as a transcriptional activator, enrichment of direct targets was analyzed for the set of up- or down-regulated
genes (A), while the gene set altered in leukemia was analyzed for deregulated genes in general (B). FDR, false discovery rate q-value; NES, normalized
enrichment score.
Fleischmann et al. Molecular Cancer 2014, 13:27 Page 4 of 14
http://www.molecular-cancer.com/content/13/1/27A high number of transcriptional regulators (38 genes)
were affected by MLL-AF9 depletion. Several (i.e. CEBPB,
FOS and FOSB) were also described to be deregulated in
the transition of CML blastic phase to an acute leukemia
[23].
Calcium associated genes as well as genes involved in re-
sponse to estrogen stimulus were strongly enriched after
MLL-AF9 depletion, implying an influence of MLL-AF9
on calcium ion homeostasis and estrogen response effects.
The enriched annotation chaperone binding contains pro-
teins which interact selectively and non-covalently with a
chaperone protein and encompassed four down-regulated
genes in our data set. The enrichment of genes within the
annotation regulation of cell size is consistent with our
phenotypic findings and encompassed the genes AR,
ATP2B2, EMP1, LAMB2, NOTCH2, PLXNA3, SGMS1,
TGFBR1 and WFDC1.
The higher-order term early development suggests
downstream effects of MLL-AF9 analogous to MLL andTable 1 Gene set enrichment analysis of leukemia patient stu
Patient study gene sets R
Top-100 gene set of MLL AML K
Top-100 gene set of MLL leukemia irrespective of lineage K
Top-100 probe set of pediatric MLL AML R
Downregulated in MLL AML R
Gene cluster 1 and 16 of 11q23 abnormal AML V
CML-BP versus CML-CP Z
Downregulated in CML-BP versus CML-CP Z
Corresponding gene set enrichment plots are displayed in Additional file 3: Figure S
leukemia blastic phase; CML-CP, chronic myeloid leukemia chronic phase; FDR, falseAF9 wildtype proteins. This concerns effects on pattern
specification processes, mainly via homeobox genes. Other
enriched annotation terms suggested an influence of
MLL-AF9 on genes involved in aging and on genes encod-
ing proteins of the actin cytoskeleton and the extracellular
matrix.
GSEA analysis for our entire gene expression profile
(which does not employ a significance cutoff value) add-
itionally suggested effects on DNA repair, MAP kinase
activity, RNA polymerase activity, splicing, ribosomal
constituents and translation (Additional file 2).
We further asked which of the functional processes in-
fluenced by MLL-AF9 are due to direct effects of MLL-
AF9. For this purpose, we performed a gene ontology
enrichment analysis (DAVID) for previously published
direct targets of MLL-AF9 derived from a mouse model
[13] (Additional file 4) and compared the results to our
gene ontology data. The overlap between the data sets
suggests that transcriptional regulators such as thosedies for our MLL-AF9 knockdown gene expression dataset
eference FDR q-value NES
ohlmann et al. [1] 0.008 1.48
ohlmann et al. [1] 0.020 1.40
oss et al. [20] 0.022 1.38
ozovskaia et al. [21] 0.005 1.69
alk et al. [22] 0.030 1.34
heng et al. [23] <0.001 1.96
heng et al. [23] <0.001 2.08
1. MLL AML, MLL aberrant acute myeloid leukemia; CML-BP, chronic myeloid
discovery rate; NES, normalized enrichment score.
Figure 3 MLL-AF9 knockdown associated enriched functional gene annotations identified via DAVID. Enriched annotation terms (fold
enrichment (FE) ≥ 1.5 and p < 0.1) were manually assorted to six higher-order terms according to the major role of the process in the biological
setting under investigation. Annotation terms assigned to two higher-order terms are indicated by dotted division lines between these two.
Annotation terms which could not be assigned to one of the five specific higher-order terms are depicted under the term “other”. Some
annotations were abbreviated as indicated by superscript numbers: 1Antigen processing and presentation of peptide or polysaccharide antigen
via MHC class II, 2Regulation of transcription from RNA polymerase II promoter. Columns show proportion of down- (white) and up-regulated
(black) genes after MLL-AF9 knockdown in THP1 cells. All differentially expressed genes contained in each functional annotation term are given in
Additional file 4 together with the term identifier, FE and p value of the terms.
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mainly direct MLL-AF9 targets. On the other hand, the
majority of processes we identified as affected by MLL-
AF9 depletion (like apoptosis, calcium and estrogen re-
lated genes and monocyte/macrophage differentiation) are
likely governed by indirect effects of MLL-AF9.MLL-AF9 knockdown is associated with reduced cell size
We did not observe effects of MLL-AF9 depletion on pro-
liferation, cell cycle distribution and apoptosis rate of
THP1 cells (Additional file 3: Figure S2). However, we
consistently detected a significant reduction of 0.2 μm in
mean cell diameter between MLL-AF9 knockdown and
control treatments (Figure 4A). MLL-AF9 specific reduc-
tion in cell size was evident under serum reduced condi-
tions and prolonged MLL-AF9 knockdown but not in the
presence of 10% FCS (up to day 8) or upon a shorter time
frame (up to day 3).Cell size has previously been described to be closely
linked to ribosomal biogenesis [28]. GSEA indeed revealed
genes encoding structural constituents of ribosomes to be
significantly enriched in down-regulated genes after MLL-
AF9 knockdown in THP1 cells (Figure 4B). The core
enrichment gene set was represented by 42 ribosomal pro-
teins of small and large subunits of both, cytoplasmic and
mitochondrial ribosomes.
Target genes likely mediating MLL-AF9
leukemogenic effects
Among the 425 differentially expressed genes, 41 candi-
dates for mediation of MLL-AF9 leukemogenic effects were
prioritized by a stepwise approach (Figure 5). Selected were
(1) genes with strongest differential expression (≥ ± 1.0 log2
fold change (log2FC)), (2) leukemia associated genes defined
by functional disease ontology (FunDO), (3) the strongest
regulated (≥ 1.0 log2FC and further top 5) genes of each
higher-order term from functional gene annotation results
Figure 4 Effects of MLL-AF9 knockdown in THP1 cells related to cell size. (A) Mean cell diameter between MLL-AF9 knockdown and
non-targeting siRNA control cells was significantly altered on day 7 and 8 of experiments. Graph represents data from five independent experiments.
Bars indicate standard deviation. **p < 0.005. (B) Gene set enrichment plot of genes from the gene ontology term “structural constituent of
ribosome” (GO:0003735) for our gene expression profile after MLL-AF9 knockdown in THP1 cells. FDR, false discovery rate; NES, normalized
enrichment score.
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sion between our in vitro data and published leukemia pa-
tient studies. Due to overlapping hits, this added up to 70
genes which were subsequently subjected to literature re-
search and rated via a structured strategy (Additional file 3:
Table S2). This approach resulted in 41 genes being rated
as likely mediators of leukemogenic effects of MLL-AF9
(Figure 6).
Receptors, including nuclear receptors (i.e. ligand-
activated transcription factors), enzymes and transporter
have yielded especially successful therapeutic targets for
clinical intervention [11]. Thus, we judged those amongFigure 5 Strategy to prioritize candidate genes concerning
mediation of MLL-AF9 leukemogenic effects. Four approaches
(second line) were used to select 70 genes from the set of 425
differentially expressed genes after MLL-AF9 knockdown in THP1
cells. Each gene’s likelihood to play a role in leukemogenesis was
rated via a structured rating strategy based on data obtained
through a literature search.our 41 top rated genes which encode receptors, enzymes
or transporter as potential therapeutic targets down-
stream of MLL-AF9. An overview of the relevant bio-
logical roles of these seven potential therapeutic targets,
including the dopamine receptor DRD5, is presented in
Table 2.
The dopamine receptor antagonist SCH39166 exerts
effects on malignant cell characteristics of THP1 cells
As a proof of principle for the functional relevance of
the suggested therapeutic targets, we examined the ef-
fects of the DRD1- and DRD5-specific dopamine recep-
tor antagonist SCH39166 (ecopipam) on THP1 cells.
Treatment of THP1 cells with 10 μM SCH39166 led to a
number of significant changes in cell characteristics: (1)
proliferation and (2) colony forming capacity were reduced,
(3) cell cycle analysis revealed alternating changes in G1
and S phase distributions which may suggest a slowdown
of cell cycle progression, (4) cells were slower to reach G0/
G1 phase after DNA new synthesis which was reduced and
(5) the cell migration rate was decreased (Figure 7). No in-
crease in the rate of apoptotic THP1 cells was observed
(Additional file 3: Figure S3).
Discussion
The experimental setup of this RNA interference study was
optimized to exclude off-target effects and to ensure a spe-
cific reduction of MLL-AF9 protein on functional level.
Among seven human cell lines carrying the MLL-AF9
translocation, the cell line THP1 was chosen for this study
because it is the only one established from a characteristic
infant AML M5 leukemia patient [29]. According to gen-
omic DNA gains and losses as well as gene expression,
THP1 – like other leukemia cell lines – has been described
to be a faithful model system for leukemia with genomic
aberrations [30]. As compared to overexpression studies,
Figure 6 Differential expression after MLL-AF9 knockdown of genes considered as likely mediators of MLL-AF9 leukemogenic effects.
Columns show log2FC from microarray data of MLL-AF9 knockdown versus control treatments on day 8. Standard error of the mean is indicated.
Transcripts are sorted according to categories of encoded proteins and alphabetically. Dotted division lines indicate proteins assorted to two
categories. *Genes coding for proteins which belong to conventionally druggable protein classes as described by Rask-Andersen et al. [11].
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range and to target all putative transcript variants of MLL-
AF9 which retain the breakpoint exons.
The validity of the generated differential gene expression
profile as well as the suitability of our experimental ap-
proach was supported by the significant enrichment of
several gene sets generated by previous studies: Leukemia
was the top ranked associated disease term, and direct
MLL-AF9 murine targets [13] as well as MLL-AF9 down-
stream genes detected in transduced neonatal and myeloid
as well as lymphoid human primary cells [14] were signifi-
cantly enriched. These findings validate our experimental
approach in that expected information content was indeed
disclosed in our data. It also indicates that our MLL-AF9
knockdown model represents neonatal and mixed lineage
features as expected forMLL-AF9 positive leukemia.
Additionally, concordance of our in vitro model system
to the in vivo situation was suggested by enrichment of
MLL associated gene signatures from various myeloid
leukemia patient studies. Among the enriched signatures
were those of four AML patient studies but also one dataset characterizing CML leukemia blastic phase as compared
to chronic phase [23]. As this step marks the transition to
an acute leukemia [23], the overlapping genes (CEBPB,
FOS, FOSB, IL8, S100A12, SOCS2) might be involved in the
aggressiveness ofMLL-AF9 myeloid leukemia blasts.
To characterize biological processes influenced by MLL-
AF9, we performed functional studies in our experimental
system and employed functional gene ontology analyses
on our MLL-AF9 modulated gene expression profile
which encompassed 425 differentially expressed genes.
Most remarkable in our functional results was a signifi-
cant reduction of cell size in MLL-AF9 depleted THP1
cells. Enriched differential expression of genes within the
annotation regulation of cell size (e.g. ATP2B2 and EMP1)
was consistent with this observation. The annotation
terms structural constituents of ribosomes and cellular cal-
cium ion homeostasis were also linked to our data set and
could contribute to the observed cell size reduction. Ribo-
somal biogenesis is a known important determinant of cell
size [28] and has been linked to tumorigenesis and malig-
nancies [31], while intracellular Ca2+ levels can regulate
Table 2 Genes deregulated by MLL-AF9 and prioritized as potentially druggable targets in MLL-AF9 leukemia
Gene log2 FC Protein class Official full name
Biological role
AHR 0.44 Nuclear receptor Aryl hydrocarbon receptor
Upregulated by AML associated fusion gene AML1-ETO. Differentiation of myeloblastic
leukemia cells. Estrogen receptor degradation. AHR knockout mice display CML.
ATP2B2 −0.69 Transporter ATPase, Ca++ transporting, plasma membrane 2
Lowers intracellular calcium; protects from apoptosis.
DRD5 −0.96 Receptor Dopamine receptor D5
Raised after G-CSF treatment; dopamine receptor agonists activate Wnt signaling,
induce migration and increase clonogenic capacity and repopulation of CD34+ cells.
HIPK2 0.5 Enzyme Homeodomain interacting protein kinase 2
Phosphorylates transcription (co-) factors (e.g. c-Myb); may trigger
(myeloid) differentiation and apoptosis. Mutations found in AML cases.
PARP8 −0.63 Enzyme Poly (ADP-ribose) polymerase family, member 8
Phosphorylated upon DNA damage. Upregulated in MLL rearranged AML patients.
ROR2 0.81 Receptor/enzyme Receptor tyrosine kinase-like orphan receptor 2
Mediates noncanonical Wnt signaling. Putative tumor suppressor in leukemia,
presumably via inhibition of Wnt canonical signaling.
TAS1R3 −2.01 Receptor Taste receptor, type 1, member 3
Glucose absorption/energy supply. Heterodimers sense extracellular
amino acids, activate MTORC1 and inhibit autophagy.
Details to biological roles and references are given in Additional file 3: Table S2. Log2FC: log2 fold change in MLL-AF9 knockdown relative to control.
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Cl- channels [32].
Enrichment of annotation terms related to proliferation
and apoptosis implied that MLL-AF9 is involved in repli-
cation and cell death via downstream transcripts. Previous
studies have detected effects of MLL-AF9 on these
cellular characteristics after treatment with antisense
phosphorothioate-oligodeoxyribonucleotides [33,34]. In
our hands, however, neither the proliferation rate nor
the proportion of apoptotic THP1 cells was detectably
altered after MLL-AF9 knockdown. This might be due
to favorable in vitro growth conditions and the absence
of sufficient apoptosis stimuli in our cell culture situ-
ation. Nevertheless, the differential gene expression sig-
nature generated in this study yielded genes which can
influence apoptosis and might contribute to the mito-
genic phenotype of MLL-AF9 positive monoblasts in a
less ideal environment possibly present in the in vivo
disease state. These genes encode for example POT1
which promotes telomere elongation [35], CALR which
promotes DNA synthesis and inhibits growth arrest and
senescence (via p21) [36] and HIPK2 which is involved
in induction of cell death and differentiation [37].
MLL-AF9 is regarded as a class II mutation, primarily
interfering with cellular differentiation [38]. In line with
this, a major effect of MLL-AF9 on monocytic differenti-
ation was also revealed by our data: Numerous signifi-
cantly enriched, functional annotation terms concerned
fundamental functions of monocytes and macrophages.Moreover, the differential expression of nine marker genes
clearly suggested maturation of MLL-AF9 depleted THP1
monoblasts. This implies that the MLL-AF9 induced differ-
entiation stop is, at least in part, reversible. It is thus tempt-
ing to speculate that therapeutic differentiation strategies as
successfully employed for acute promyelocytic leukemia
[39] might also be feasible forMLL aberrant AML.
The enriched annotations response to estrogen stimu-
lus and chaperone binding might also be related to
leukemogenic mechanisms. MLL-AF9 might inhibit es-
trogen receptor degradation and retinoic acid signaling
pathways leading to impaired cellular differentiation:
AHR and MAPK15 which are reported to target estro-
gen receptor alpha to degradation [40,41] were reduced
in their expression by MLL-AF9 in our study. Estrogen
and retinoic acid signaling are known to regulate gene
expression in opposing directions [42]. Furthermore,
promoter methylation (indicating transcriptional re-
pression) of estrogen receptor is associated with in-
creased survival of AML patients and reduced in AML
M5 [43]. Chaperones have been linked to deregulated
cell growth as forced overexpression of chaperones was
shown to result in cellular transformation and tumor
formation [44]. Within our data set, all four chaperone
binding genes were down-regulated. One of these, calre-
ticulin, encodes a multifunctional protein which acts
also as chaperone and is known to inhibit the transla-
tion of CEBPA, a key myeloid transcription factor fre-
quently disrupted in AML [45].
Figure 7 THP1 cell characteristics influenced by 10 μM of the dopamine receptor antagonist SCH39166 compared to DMSO control.
(A) Proliferation in serum reduced conditions. (B) Colony formation in methyl cellulose. Images show representative wells of DMSO control (left)
and 10 μM SCH39166 treatment (right). (C) Cell cycle distribution in serum reduced conditions. (D) Cell migration in 5 μm transwells. (E) DNA
new synthesis rate measured via EdU incorporation and SYTOX AADvanced nuclear stain. Ratio of SCH39166 compared to DMSO control
treatment is shown. Mean over three (A-C) or two (D-E) independent experiments are shown. Bars indicate standard error of the mean;
*p < 0.05. † Non significant differences because of interexperimental fluorescence intensity standard deviation, although the ratio between the
two treatments remains similar.
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expression was suggested by significantly enriched an-
notations encompassing 38 differentially expressed tran-
scription factors. One example is the up-regulation of
CIITA, the master coactivator of MHC class II [46].
Accordingly, in MLL-AF9 depleted THP1 cells, we
observed an up-regulation of all MHC class II genes
(HLA-DP, -DQ, -DR, -DM) with exception of the non-
classical HLA-DO which seems less dependent on the
CIITA transcription factor [46]. Up-regulation of HLA
class II gene transcripts has previously been associated
with differentiation of monoblasts, while THP1 cells
were observed to have reduced HLA class II expression
levels compared to mature monocytes [24].Results from functional annotation analysis indicated
that MLL-AF9’s direct targets are predominantly tran-
scriptional regulators while other processes we identified,
like monocyte/macrophage differentiation or estrogen re-
sponse are likely related to indirect effects of MLL-AF9.
Although considerable progress has been made, transcrip-
tion factors have been found difficult to target therapeutic-
ally [47]. This emphasizes the importance of determining
indirect targets downstream of MLL-AF9 to identify MLL-
AF9 leukemogenic effectors amenable to be addressed by
small molecule drugs.
We are aware that our prioritization strategy to select
candidate targets is not all-inclusive. Some candidates may
be lost during the primary subset selection or by our
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on these gene products. Our comprehensive gene expres-
sion data set (GEO: GSE36592) may thus hold a yet vaster
source of informative content. Nevertheless, we prioritized
41 candidates potentially involved in mediation of MLL-
AF9 leukemogenesis. Among these are many novel as only
26 were identified in previousMLL-AF9 studies [3,13,14,48]
and only one, HOXA9, is a known direct target of MLL-
AF9. Some of our candidates are potential therapeutic tar-
gets, primarily those encoding receptors, enzymes, and
transporter: These classes represent almost 90% of all
therapeutic effect-mediating human protein targets of drugs
listed by the US Food and Drug Administration (FDA) [11].
Seven of our top-41 candidates encode proteins of these
classes: AHR, ATP2B2, DRD5, HIPK2, PARP8, ROR2 and
TAS1R3.
As a proof of principle, we selected one of these sug-
gested targets, the dopamine receptor DRD5, for further
investigation. Expression of DRD5 is raised in CD34+
hematopoietic progenitor cells after G-CSF treatment and
dopamine receptor agonists activate Wnt signaling, induce
migration and increase clonogenic capacity and repopula-
tion in this cell type [49].
We employed the drug SCH39166 (ecopipam) which
is currently one of the most specific antagonists for the
dopamine receptor DRD5 and antagonizes DRD1 and
DRD5 receptors but not receptors of the DRD2-class.
Treatment of THP1 cells with SCH39166 exerted a
number of significant anti-malignant effects, i.e. affecting
proliferation, clonogenic capacity, cell cycle distribution,
DNA new synthesis and cell migration.
The safety profile of SCH39166 has been studied in
over 1000 people and SCH39166’s ability to ameliorate
multiple central nervous system diseases is under in-
vestigation in clinical phase 1–3 trials (Psyadon Phar-
maceuticals, Inc.). In a large compound screening
study, Sachlos et al. recently discovered that thiorida-
zine - which antagonizes the dopamine receptors 1 to
5 – selectively targets neoplastic cells and human
leukemic stem cells. In contrast, no effects of thiorida-
zine were reported on normal blood stem cells which
do not express dopamine receptors [50].
Previous data also indicate an influence of some of
our suggested therapeutic targets e.g. on cellular differ-
entiation, Wnt signaling and apoptosis (Table 2). The
nuclear receptor AHR e.g. has been shown to promote
retinoic acid–induced differentiation of HL-60 myelo-
blastic leukemia cells, if overexpressed [40] while AHR
knockout mice are diagnosed with CML [51]. DrugBank
search results [52] revealed that AHR and DRD5 inter-
act with 6 and 18 approved drugs respectively, although
developed for other medical indications. The candidates
ATP2B2, PARP8 and TAS1R3 have previously not been
functionally linked to leukemia.The present study provides a comprehensive gene ex-
pression profile after MLL-AF9 knockdown in THP1 cells
that broadens our insights into the molecular mechanisms
and druggability ofMLL aberrant leukemia. The finding of
a more differentiated state of THP1 cells after MLL-AF9
depletion is consistent with the hypothesis that the MLL-
AF9 induced differentiation stop is reversible. We describe
here more than 40 gene products and several cellular pro-
cesses likely involved in mediation of leukemogenic effects
of MLL-AF9. Among these, seven targets were classified
as potentially druggable and targeting one of these, DRD5,
shows anti-leukemic effects in THP1 cells. Altogether, our
results might support the search for new targeted therap-
ies for MLL-AF9 positive pediatric AML.
Methods
Cell cultivation
THP1 cells (DSMZ GmbH, Braunschweig, Germany) were
maintained in RPMI1640, 10% heat-inactivated fetal calf
serum (FCS), 100 U/ml Penicillin and 0.1 mg/ml Strepto-
mycin (PAA Laboratories, Pasching, Austria) at a density
of 0.05-0.5 × 106 cells/ml. To minimize the effect of FCS
on growth related and mitogenic signaling pathways,
serum levels were reduced from experimental day 6
onwards. Serum reduced conditions were achieved by
washing cells in PBS and resuspending them in DMEM/
Ham’s-F12 medium containing 1 g/L BSA and 0.5% Fetal
Bovine Serum (Gibco, Life Technologies, Carlsbad, CA,
USA). For functional studies of DRD5, THP1 cells were
treated with 10 μM SCH39166/ecopipam (Tocris Bio-
science, Bristol, UK) or DMSO as control.
Small interfering RNA and transfection
Silencer Select siRNAs (siRNA-A, siRNA-B, negative con-
trol siRNA-1 and −2, Ambion, Life Technologies) were
dissolved in 1 x siRNA buffer (Dharmacon, Lafayette, CO,
USA). SiRNA-A and -B sequences are shown in Figure 1A.
Transfections were performed according to the supplier’s
protocol with 9 μl Dreamfect (OZ Biosciences, Marseille,
France) at a final concentration of 50 nM siRNA within
1 ml culture medium that contained 5 × 104 cells in a 12-
well format (Greiner, Kremsmuenster, Germany). Trans-
fection efficiency was measured by flow cytometry with
fluorescently labeled control siRNA.
Experimental incubations lasted eight days with repeated
transfections on day 0, 3, and 6. Prior to each transfection
event, cell densities were determined by Cellscreen System
(Innovatis, Bielefeld, Germany) on an Olympus IX 50
microscope (Olympus, Tokyo, Japan) and cells were subse-
quently reseeded at 5 × 104 cells per ml.
RNA isolation and reverse transcription quantitative PCR
Total RNA was extracted with miRNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the supplier’s
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qPCR) was carried out in triplicates with 600 ng total
RNA, QuantiTect Reverse Transcription Kit (Qiagen)
and iQ™-SYBR® Green Supermix (Biorad, Hercules, CA,
USA) on a StepOnePlus instrument (Applied Biosystems,
Life Technologies) according to the supplier’s protocol.
RPL13A and UBC, showing stable expression in bone
marrow [53], were used as reference genes. Data were ana-
lyzed with StepOne software v 2.1 (Applied Biosystems)
and the ΔΔCq method. Primer sequences are provided in
Additional file 3: Table S3.
Immunoblotting
Total cellular protein was recovered from Qiazol organic
phase according to TRI reagent protein isolation protocol
(Ambion), resuspended in 9.5 M urea, 4% [w/v] CHAPS,
mixed 1:1 with Laemmli sample buffer (2×, Sigma-Aldrich,
St. Louis, MO, USA) and incubated 5 minutes at 95°C. Pro-
teins were separated by SDS-PAGE and transferred onto
PVDF membrane in transfer buffer (10 mM CAPS, pH 11,
10% methanol, 0.01% SDS). Membranes were probed with
anti-MLL1, anti-AF9 (A300-086A, A300-597A, Bethyl La-
boratories, Montgomery, TX, USA), anti-Lamin A/C and
secondary antibodies (sc-7292, sc-2004, sc-2005, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) followed by detec-
tion using ECL-substrate. Band intensities were analyzed
with ImageJ version 1.46r (National Institutes of Health,
Bethesda, MD, USA).
Gene expression profiling analysis
Human Whole Genome Microarrays 4x44K v2 (Agilent
Technologies, Santa Clara, CA, USA) were commissioned
to and performed at IMGM Laboratories (Martinsried,
Germany). Two knockdown (siRNA-A, siRNA-B) and two
negative control siRNA samples, each containing 100 ng
pooled RNA of five independent experiments were uti-
lized. RNA concentration and purity (abs 260/280 nm)
were analyzed using a Nanodrop ND-1000 Spectropho-
tometer (Nanodrop Technologies, Wilmington, DE, USA).
RNA integrity was determined with an RNA 6000 Nano
LabChip Kit on a 2100 Bioanalyzer (Agilent Technolo-
gies). A260/A280 was above 2.0 and RNA integrity num-
ber was above 9.3.
Hierarchical clustering of arrays and principal compo-
nent analyses were performed with the statistical language
R version 2.11.1 [54] using packages from the Bioconduc-
tor framework [55]. Analysis of differential expression was
carried out in R with the limma package [56,57]. Adjust-
ment for multiple testing was done using the method by
Benjamini and Hochberg [58]. For differential expression
analysis, the unnormalized data were favored over the
normalized as they showed an almost perfect and super-
ior logarithmic intensity distribution. Normalized values
showed no improved principal component analysis andhierarchical clustering concerning similarity of biologically
related arrays. Unnormalized identical replicate probes
yielded more consistent intensity values compared to the
normalized values which further supported this approach.
Probes were considered as differentially expressed at a p-
value of the moderated t test below 0.005 and significant
alteration over all identical replicate probes (t test, p < 0.05).
To test reliability of microarray data, RT-qPCR was per-
formed for 14 arbitrarily selected transcripts which showed
differential expression in microarray results (ARHGAP26,
CALR, CEBPB, CIITA, FOS, FUCA1, MAFB, NOTCH2,
SOCS2, SULF2, TSPAN14, VASH1, VDR and ZNF521).
Spearman’s rank correlation coefficients including p values
were calculated with R. Spearman’s Rho was 0.91 (p 5.15 ×
10-6) for technical replicates (identical RNA samples in RT-
qPCRs and microarrays) and 0.72 (p 0.004) for biological
replicates (RT-qPCRs performed on RNA sample pools of
2 independent experiments).
Functional bioinformatics
Functional disease ontology (FunDO) [59] and functional
annotation analysis (Database for Annotation, Visualization
and Integrated Discovery version 6.7, DAVID) [19] was per-
formed with input of all 425 differentially expressed genes.
Enrichment was regarded as significant if fold enrichment
was ≥ 1.5 and p-value < 0.1. Functional annotation analysis
of direct targets of MLL-AF9 was performed with a previ-
ously published gene list [13] transformed to the official
gene symbols. Gene set enrichment analysis was executed
with the computational method GSEA version 2.0 [60,61].
Gene sets associated to leukemia were extracted from
FunDO and from leukemia patient studies [1,20-23] and
transformed to the official gene symbols. Parameter settings
were default except for: dataset was not collapsed to gene
symbols, instead the strongest regulated probe per gene
was selected; gene set was selected as permutation type;
metric for ranking genes was log2 ratio of classes; gene
list sorting mode was either real for gene sets including
only up- or down-regulated genes or abs for gene sets
including up- and down-regulated genes. A rating strat-
egy for prioritization of genes likely mediating MLL-
AF9 leukemogenic effects was devised as outlined in
Additional file 3: Table S4.
Biological assays
Proliferation and cell diameter were measured via Cellsc-
reen System (Innovatis) on an Olympus IX50 microscope.
This microscopic monitoring system provides fully auto-
mated non-invasive cell count in cell culture well plates by
generating microscopic images at defined regions of inter-
est (ROIs). By digital image recognition, cells are automat-
ically detected, counted and their geometry (diameter and
eccentricity) is analyzed [62]. Measurements were per-
formed in 12-well plates (Greiner) with 62 ROIs per well
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allowed to settle for 20 minutes prior to measurement. A
Welch’s t test was performed over replicate experiments
after confirmation of normal distribution via Shapiro-Wilk
normality test.
Cell cycle analyses were performed via flow cytometry.
Cells were fixed in 70% ethanol at −20 °C, subsequently
stained for 30 min with propidium-iodide (0.1% Triton X-
100, 0.2 mg/ml RNase A, 20 μg/ml propidium-iodide in
PBS) and analyzed on a BD FACSCanto™ (BD Biosciences,
Franklin Lakes, NJ, USA). Cell doublets and aggregates
were removed by gating and the proportion of cells in G0/
G1, S and G2 phase were quantified with Watson Prag-
matic model in FlowJo 9.7.2. DNA new synthesis rate was
measured by flow cytometry after pulse labeling THP1 cells
with 25 μM EdU (5-ethynyl-2’-deoxyuridine) for 2 hours
and staining with AF488-azide and SYTOX AADvanced
nuclear stain (Invitrogen, Life Technologies) according to
supplier’s protocol. Statistics were calculated with Shapiro-
Wilk normality and Welch’s t test in R.
Apoptotic rate was analyzed via intracellular staining of
cleaved PARP1 [63]. Cells were fixed and permeabilized
with Foxp3 Staining Buffer Set (eBioScience, San Diego,
CA, USA) and stained with anti-PARP antibody (44–699,
Invitrogen) after blocking with 5 μg human IgG (Sigma).
Colony forming capacity was analyzed by plating 1000
THP1 cells in 1 ml 0.5% methyl cellulose (64630, Sigma)/
RPMI1640 (10% FCS) in 6-well plates. Colonies were
counted in microscopic images taken after 10 days by
Cellscreen system.
Migration was analyzed in a transwell assay (5 μm pore
size, #3421, Corning, NY, USA) with 0.1 × 106 THP1 cells
in RPMI1640 / 10% FCS in upper chamber and RPMI1640
with 10% FCS and 0.1 mM ascorbic acid in lower cham-
ber. Cells in lower chamber were counted in microscopic
images taken after 20 hours by Cellscreen system.
For analyses of SCH39166 effects, cells were pre-treated
with drug or DMSO for 3 hours prior to performing
assays.Additional files
Additional file 1: Differentially expressed probes in MLL-AF9
knockdown. Listed are all differentially expressed probes (p < 0.005)
from gene expression arrays of MLL-AF9 depleted versus control THP1
cells on day 8 of experiments.
Additional file 2: Gene set enrichment analysis (GSEA) results.
(Sheet 1) GSEA of gene sets identified by Horton et al. [14] employing
MLL-AF9 transduced primary human cells for the MLL-AF9 knockdown
gene expression profile of this study. “Up” or “down” indicates gene sets
comprising either up- or down-regulated genes after MLL-AF9
transfection of cord blood (neonatal) or bone marrow (adult) CD34+ cells
by Horton et al. [14]. (Sheet 2) GSEA of gene ontology (GO) terms for the
gene expression profile after MLL-AF9 knockdown in this study (false
discovery rate < 0.05).Additional file 3: Figures S1-S3 and Tables S1-S4. Figure S1. GSEA
enrichment plots of published leukemia patient studies for our MLL-AF9
knockdown gene expression profile. Table S1: Assignment of enriched
functional annotation terms to higher-order terms. Figure S2: Cell
characteristics of MLL-AF9 depleted and control THP1 cells. (A) Proliferation.
(B) Cell cycle distribution. (C) Apoptosis rate. Figure S3: Apoptosis rate in
THP1 cells treated with 10 μM SCH39166 compared to DMSO control.
Table S2: Biological roles and rating of 70 selected genes differentially
expressed after MLL-AF9 knockdown. Table S3: Primer used for reverse
transcription quantitative PCR. Table S4: Rating strategy to prioritize
candidate targets for mediation of MLL-AF9 leukemogenic effects. A
total of 70 differentially expressed genes after MLL-AF9 knockdown was
rated.
Additional file 4: Results of gene ontology analyses performed via
DAVID software. Terms were regarded as significantly enriched if fold
enrichment was ≥ 1.5 and p value ≤ 0.1. (Sheet 1) Significantly enriched
annotation terms which were regarded as potentially relevant in this
biological setting. Terms were identified via DAVID analysis of our gene
expression profile after MLL-AF9 knockdown. Table includes the
differentially expressed genes of each term. (Sheet 2) All significantly
enriched functional gene ontology terms identified for our gene
expression profile after MLL-AF9 knockdown. (Sheet 3) Significantly
enriched functional gene ontology terms for direct MLL-AF9 targets
identified in a mouse model by Bernt et al. [13].
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